Furthermore, RUNX1 enhanced the progression and metastatic capabilities of colorectal cancer by upregulating MUC13, which resulted in an increased EMT phenotype and amplified Wnt/β-catenin pathway activity. Here, MUC13 is linked to colorectal cancer.